China Pharmaceutical University and Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. have jointly developed Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.

Proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to non-receptor tyrosine-protein kinase TYK2-targeting moiety have been reported in a Kymera Therapeutics Inc. patent as potentially useful for the treatment of neurological, inflammatory and endocrine disorders, autoimmune diseases, transplant rejection, graft-vs.-host disease and cancer.

Recent Perha Pharmaceuticals patents describe imidazolone derivatives acting as inhibitors of dual specificity protein kinase CLK1 and/or CLK4 and/or and dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). As such, they are reported to be useful for the treatment of diabetes, cancer, CDKL5 deficiency disorder, chromosome 22q13 deletion syndrome, Alzheimer’s disease, viral infections, Niemann-Pick disease type C and tauopathies, among others.

Marvel Biotechnology Inc. has reported the identification of compounds potentially useful for the treatment of depression.

A Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details piperidinyl indole derivatives acting as complement factor B (CFB) inhibitors.

Research at Reunion Neuroscience Inc. has led to the discovery of benzyltryptamine compounds acting as 5-HT2A receptor agonists. These compounds are reported to be useful for the treatment of depression, alcoholism, cocaine addiction, inflammation, cluster headache neurological and post-traumatic stress disorder.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified piperazinylsulfonylaryl compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors.

A recent Twentyeight-Seven Inc. patent describes dual specificity protein kinase CLK3 inhibitors reported to be useful for the treatment of cancer.

Cancer Research Technology Ltd. and Merck KGaA have jointly patented tricyclic heterocycles acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors.

An Insilico Medicine IP Ltd. patent describes Egl nine homolog 1 (EGLN1; HPH-2; PHD2) inhibitors reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.